HealthInvest Partners AB Increases Stock Position in Edwards Lifesciences Co. (NYSE:EW)

HealthInvest Partners AB lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 87.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,296 shares of the medical research company’s stock after buying an additional 31,791 shares during the period. Edwards Lifesciences comprises 2.4% of HealthInvest Partners AB’s investment portfolio, making the stock its 15th biggest holding. HealthInvest Partners AB’s holdings in Edwards Lifesciences were worth $5,070,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $555,939,000. Assenagon Asset Management S.A. boosted its stake in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after acquiring an additional 2,606,950 shares during the period. Finally, Seilern Investment Management Ltd purchased a new position in Edwards Lifesciences in the 4th quarter valued at approximately $109,490,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on EW shares. Morgan Stanley boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Piper Sandler increased their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group lifted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $79.95.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 2.0 %

Shares of EW stock opened at $73.25 on Monday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm’s 50-day simple moving average is $72.85 and its 200-day simple moving average is $70.06. The firm has a market cap of $43.20 billion, a P/E ratio of 10.51, a PEG ratio of 4.82 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.